Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Dartmouth Health

Status and phase

Completed

Phase 4

Conditions

Psychotic Disorders

Schizophrenia

Alcohol Abuse

Substance Abuse

Treatments

Drug: Risperidone Long Acting

Drug: oral risperidone

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00130923

17359

RIS-EMR-4032

Details and patient eligibility

About

The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with schizophrenia or schizoaffective disorder.

Full description

Comorbid alcohol/substance use disorder (SUD) in people with schizophrenia is a major concern, both in view of the high frequency of SUD among patients with schizophrenia and the difficulty in managing such patients. Though antipsychotic medications are effective in reducing symptoms and impairment in persons with schizophrenia, the typical antipsychotic agents are of limited value in controlling alcohol/substance use in these patients. Extrapyramidal, dysphoric side effects of conventional neuroleptics may actually promote the use of substances in an attempt to counteract these effects. In addition, medication non-compliance is common among patients with schizophrenia.

Novel antipsychotics have altered treatment expectations and outcomes for patients with severe forms of schizophrenia. A growing number of studies have assessed the effects of oral risperidone in persons with dual disorders. Potential mechanisms of action by which risperidone and other atypical antipsychotics could decrease substance use include being less likely to cause extrapyramidal side effects than typical agents, improving negative symptoms and ameliorating a dysfunction of the brain reward system. Risperidone long-acting injectable medication addresses issues of noncompliance, while avoiding peak blood levels of oral preparations, thereby minimizing EPS and improving negative symptoms of schizophrenia. Risperidone may also facilitate dopamine neurotransmission in the prefrontal cortex and correct a hypothesized dysfunction of the brain reward system.

This study is an open, randomized, controlled study to compare intramuscular long-acting risperidone to oral risperidone with blinded ratings to determine whether the long-acting form of risperidone has greater efficacy in reducing substance use. Patients with schizophrenia or schizoaffective disorder, age 18 to 65, who are taking any single oral antipsychotic medication except clozapine or risperidone long-acting may be enrolled.

Enrollment

95 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ages 18-65
Schizophrenia or schizoaffective disorder
Meets the Structured Clinical Interview for DSM-IV (SCID) criteria for an alcohol use disorder
Alcohol use on at least 5 days during the 4 weeks prior to randomization
Patient is medically stable to start either form of risperidone.

Exclusion criteria

Current treatment with clozapine.
Current treatment with injectable risperidone long-acting.
Currently pregnant, planning to become pregnant, or unwilling to use an acceptable form of birth control.
Change in medications (dose of current medication, discontinuation of medication, or new medication) in past 30 days.
History of or current breast cancer.
History of intolerance of or allergy to risperidone or risperidone long-acting.
Currently residing in a residential program designed to treat substance use disorders.
Current treatment with long-acting, injectable antipsychotic medication will require a review by the medication adjustment group before entering the client into the study.
Past treatment with risperidone long-acting will require a review by the medication adjustment group before entering the client into the study.
Treatment at baseline with a second antipsychotic medication will require a review by the medication adjustment group before entering the client into the study.
Treatment at baseline with a psychotropic agent proposed to curtail substance use will require a review by the medication adjustment group before entering the client into the study.
Patients who, in the opinion of the investigator, are judged unsuitable to participate in the study.